It doesn’t look like COVID is going away any time soon. Luckily, the vaccine has been effective, but one of the major issues with the vaccine are the side effects. This company may have a solution.
Medolife Rx, Inc. is a global integrated biopharmaceutical company and a subsidiary of Quanta, Inc. (OTCPK:QNTA). Today the firm announced positive clinical observations made on its lead drug candidate Escozine® on side effects of the COVID vaccine.
Typical vaccine side effects are similar to symptoms of the actual COVID-19 virus, including body cough, aches, fatigue and fever, among others and doctors noted that patients given Escozine® experienced significantly lessened side effects.
Medolife will be engaging an additional pilot study on the drug, looking to prove its effectiveness in decreasing side effects of vaccinations for COVID-19.
In a down day for markets, shares were trading flat at $0.041 in mid-afternoon trade.
Related Stories
